Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $67.8 million.

  • Kymera Therapeutics' Total Current Liabilities rose 7.58% to $71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 7.58%. This contributed to the annual value of $67.8 million for FY2024, which is 20.92% down from last year.
  • As of FY2024, Kymera Therapeutics' Total Current Liabilities stood at $67.8 million, which was down 20.92% from $85.7 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Total Current Liabilities registered a high of $110.6 million during FY2020, and its lowest value of $67.8 million during FY2024.
  • In the last 3 years, Kymera Therapeutics' Total Current Liabilities had a median value of $71.3 million in 2022 and averaged $74.9 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Total Current Liabilities surged by 219.98% in 2020, and later fell by 22.91% in 2022.
  • Kymera Therapeutics' Total Current Liabilities (Yearly) stood at $110.6 million in 2020, then declined by 16.34% to $92.5 million in 2021, then declined by 22.91% to $71.3 million in 2022, then climbed by 20.11% to $85.7 million in 2023, then dropped by 20.92% to $67.8 million in 2024.